Last reviewed · How we verify

NCT04360954

Evaluation of Antibody Tests for COVID-19

Completed Last updated 4 June 2024
What this trial tests

trial testing Diagnostic test in COVID in 461 participants. Completed in 8 July 2020.

Timeline
23 April 2020
Primary endpoint
8 July 2020
8 July 2020

Quick facts

Lead sponsorWashington University School of Medicine
StatusCompleted
Study typeOBSERVATIONAL
Enrollment461
Start date23 April 2020
Primary completion8 July 2020
Estimated completion8 July 2020
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Washington University School of Medicine

Who can join

18 and older, any sex, with COVID or Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the sensitivity and specificity of several marketed commercial or prototype test kits for antibody to SARS-CoV-2. The focus will be on rapid-format, point-of-care antibody test kits that detect both IgM and IgG antibodies to recombinant viral proteins. Note: No voluntary enrolment into this study will be conducted; all testing is to be conducted anonymously.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Diagnostic test

Trials testing the same drug.

Other recruiting trials for COVID

Currently open trials in the same condition.

Other Washington University School of Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04360954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing